Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06373510
Other study ID # ELCAV
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date June 20, 2024
Est. completion date April 3, 2027

Study information

Verified date April 2024
Source CerbaXpert
Contact Barbara Perniconi
Phone 0671296728
Email bperniconi@cerbaresearch.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The study would make it possible to document more explicitly the evolution of antibody titers at following a non-public vaccination over a large post-vaccination period in the French population . Analysis of real-life data would enhance knowledge of vaccine response kinetics It would be useful to identify possible early declines requiring doses Similarly, by analyzing antibody kinetics by age, sex, and vaccination status, the would be possible to determine whether there are differences in the immune response between these different sub-groups. In addition, it would provide additional information to assess the real impact of these non-public vaccines in public health and guide vaccine policies.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 10000
Est. completion date April 3, 2027
Est. primary completion date April 3, 2027
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 90 Years
Eligibility Inclusion Criteria: - Subject over 18 years of age - Subject presenting to the investigation centre as part of its usual management (prevention, screening, tracking) - Subject who has been vaccinated and/or wishes to be vaccinated - Subject able to understand the purpose of research that has given free and informed express consent - Member or beneficiary of a social security scheme Exclusion Criteria: - Protected subject: major under guardianship, curatorship or other legal protection, deprived of liberty by decision judicial or administrative

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
Blood collection
Collection of blood before and after a non mandatory vaccination

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
CerbaXpert

Outcome

Type Measure Description Time frame Safety issue
Primary Quantification of specific serum antibodies (IgM, IgG) at different times before and/or after vaccination by a reference technique such as ELISA. Quantification of specific serum antibodies (IgM, IgG) at different times before and/or after vaccination by a reference technique such as ELISA. 3 years
See also
  Status Clinical Trial Phase
Recruiting NCT04109833 - Early Antibiotic Therapy and Vaccination
Completed NCT05043168 - Kidney Histopathology After COVID-19 and SARS-CoV-2 Vaccination
Recruiting NCT05563753 - Early Antibiotic Therapy and Vaccinations in Preterm Infants
Completed NCT05160766 - Assessing Immune Response of Different COVID-19 Vaccines in Older Adults Phase 2
Not yet recruiting NCT06098703 - CARD for Community Pharmacy Vaccinations N/A
Recruiting NCT06023056 - Hepatitis B Vaccination After Neonatal Surgery
Withdrawn NCT05672654 - Evaluation of Post-SARS-CoV-2 Vaccinal Response in Immunocompromised Patients N/A
Completed NCT04934215 - Evaluation of Post-vaccination Anti-SARS-CoV-2 Serological Response in Health Care Workers With a History of COVID-19.
Recruiting NCT06294262 - Safety, Tolerability, Immunogenicity and Immunological Mechanisms of TETRALITE, a Novel Seasonal Influenza Vaccine Phase 1/Phase 2